NOVO B has posted its best week in months — up nearly 10% to DKK 307.75 — yet the forces that made the prior week's note worth reading still haven't fundamentally shifted.
The price action this week is the standout. A 9.8% weekly gain and a 2.6% single-day move on Tuesday represent a meaningful reversal from the DKK 280 levels flagged in the previous note. The one-month picture has also flipped: the stock is now up 6.5% over 30 days, erasing much of the damage that made June look so difficult. What's worth noting is that this recovery has come without any corresponding tightening in the lending market or a material rebuild of short positions — meaning the bid is coming from buyers, not short-covering.
The borrowing market remains as loose as it has been all year. Availability runs at nearly 5,000% of short interest — roughly 984 million shares sitting ready to lend against an extremely thin short base. That number has barely moved week-on-week. Cost to borrow ticked up 4% on the week to 1.10%, but that follows a month-long decline of over 10%, and the absolute level remains consistent with a stock that generates almost no speculative shorting demand. The ORTEX short score has actually drifted slightly higher over the past two weeks, from 27.5 to 28.0, but it remains in the 91st percentile for low short-squeeze risk across the universe. The borrow market, in short, tells the same story it told last week: there is no short-side pressure here, and no squeeze catalyst to speak of.
What changes the tone this week is that the stock's own earnings history backs up the buyers. At the Q1 print in early May, NOVO B rose 3.4% on the day and extended that to 4.7% over the following five sessions. The prior print in March saw a 3.1% one-day decline, but the five-day move was nearly flat at -0.3%. That's a relatively contained earnings reaction profile for a stock in the middle of a competitive firestorm — the GLP-1 pricing and pipeline concerns that dominated the narrative in the previous note haven't historically translated into outsized post-earnings volatility. The next earnings event is scheduled for August 5.
The Street picture is complicated by stale data. The most recent analyst consensus data in the ORTEX system is over 1,000 days old and should not be relied upon for target levels. What the factor scores do offer is cleaner: the EPS surprise rank sits in the 92nd percentile, meaning the company has consistently beaten estimates relative to the broader universe. The dividend score ranks in the 98th percentile — the highest tier — though the dividend history on file dates to 2022 and any yield calculation should be treated cautiously. Valuation multiples have moved modestly: the trailing PE has expanded by about 0.1x over 30 days to 13.8x, and the EV/EBITDA multiple sits near 9.9x. These are not stretched levels for a franchise of this quality, and they suggest the de-rating that hurt the stock over the past year has run some distance.
Institutional ownership underlines why this is not a stock where short sellers find easy traction. Novo Holdings holds 28.3% — a structural anchor that limits float. BlackRock and Vanguard have each been modest net buyers in their most recent reporting periods, adding just under a million shares and 610,000 shares respectively. Capital Research stands out more: it added 12.7 million shares as of its May 29 filing — the largest single institutional move in the top-15 holder list. Dodge & Cox appears as a fresh entrant, reporting 35.6 million shares against zero previously. Both moves suggest active managers were rebuilding exposure during the weakness of recent months, which may partly explain this week's recovery bid.
The question heading into August 5 is whether the stock can hold these levels through a summer with no major catalysts — or whether the competitive narrative around GLP-1 market share resurfaces to test the DKK 280-300 range again.
See the live data behind this article on ORTEX.
Open NOVO B on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
